Celyad Oncology SA CYAD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 09/17/21 EDT
4.39quote price arrow up+0.03 (+0.69%)
Volume
9,539
52 week range
3.76 - 10.31
Loading...
  • Open4.34
  • Day High4.41
  • Day Low4.29
  • Prev Close4.36
  • 52 Week High10.31
  • 52 Week High Date11/30/20
  • 52 Week Low3.76
  • 52 Week Low Date08/20/21

Key Stats

  • Market Cap68.1M
  • Shares Out15.49M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta1.39
  • YTD % Change-43.65

KEY STATS

  • Open4.34
  • Day High4.41
  • Day Low4.29
  • Prev Close4.36
  • 52 Week High10.31
  • 52 Week High Date11/30/20
  • 52 Week Low3.76
  • 52 Week Low Date08/20/21
  • Market Cap68.1M
  • Shares Out15.49M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta1.39
  • YTD % Change-43.65

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Celyad Oncology SA

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited...
Michel Lussier
Chairman
Filippo Petti
Chief Executive Officer
Gaetane Metz
Chief Operating Officer
Richard Mountfield
Vice President
Carri Duncan P.h.D.
Vice President
Address
Axis Business Park Rue Edouard Belin 2
Mont-saint-guibert
1435
Belgium